Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive Cardiolens ⦠(NCT04777513) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive Cardiolens FFR-CT Pro Method to Measure the Fractional Flow Reserve in Diagnostics of Chronic Coronary Syndromes Versus the Standard Diagnostic Modalities.
Poland450 participantsStarted 2020-08-06
Plain-language summary
A multicentre, post-marketing, observational trial in 450 patients, whose standard diagnostic workup for chronic coronary syndromes provided for Invasive Coronary Angiography (ICA). Medical records of a potential subject of the trial before their enrolment contain a good quality result of at least 128-slice CCTA performed up to 3 months before the elective ICA. CCTA should find at least one ā„50% stenosis in at least one big coronary artery of ā„ 2 mm diameter. At one hour before ICA in the latest the patient should have a resting Continuous Non-Invasive Blood Pressure (CNBP) taken with a certified device delivered by LifeFlow. The last criterion before including a patient in the final analysis is at least one significant (ā„50%) stenosis in one or two coronary arteries of ā„ 2 mm diameter visually confirmed by ICA with a FFR measurement taken in these arteries.
The data collection period will cover time from admission for the elective ICA to discharge from the hospital (evaluation of possible adverse events related to invasive procedures).
After initial qualification of available data by the attending physician, selected patients will be asked for a consent to participation in the trial no later than upon admission for the elective ICA and before CNBP measurement.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age ā„ 18
ā. Declaration of informed consent to sharing medical records gathered during the standard diagnostic workup
ā. History of chronic coronary syndromes (CCS)
ā. Diagnostic CCTA (good quality test allowing investigation of the entire coronary artery tree), showing at least one site with stenosis ā„50% of the lumen in a large coronary artery of ā„ 2 mm diameter, with no prior revascularisation
ā. Standard treatment of chronic coronary syndromes with no dosage modification required within at least 4 weeks before the enrolment
ā. Patients with a prior acute coronary syndrome (ACS) or revascularisation would be found eligible under the following conditions:
Exclusion criteria
ā. CCTA-confirmed myocardial bridges causing \>50% stenosis of the epicardial vascular lumen
ā. Coronary obstruction confirmed by CCTA or invasive coronarography
ā
What they're measuring
1
The evaluation of the increased diagnostic accuracy of the non-invasive Cardiolens FFR-CT Pro technology